Michael F Mahoney bought $2.0M of CVS Health (CVS)
Executed Feb 18 2025, disclosed Feb 19 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Feb 19 2025), the stock returned +3.2% (delay-adjusted); from the execution session (Feb 18 2025), +4.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Michael F Mahoney (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Boston Scientific Corporation (BSX). Across 1 priced purchase filing, the average 21-session return was +1.0% from execution and -2.2% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of BSX (160,901 sh across 2 lots, as filed), executed Feb 2.
Healthcare · CVS Health Corporation provides health solutions in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→